Developing a new treatment for triple-negative breast cancer
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
This study is looking at a new treatment called LG007 to see how well it works against a tough type of breast cancer called triple-negative breast cancer, using special mice that have tumors from real patients, to help find better options for people fighting this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10928807 on NIH RePORTER |
What this research studies
This research focuses on a specific and aggressive subtype of breast cancer known as triple-negative breast cancer (TNBC), which is challenging to treat with standard therapies. The study aims to investigate a novel compound called LG007 for its effectiveness against TNBC using patient-derived xenograft (PDX) mouse models. By examining how LG007 impacts tumor growth and metastasis in these models, the research seeks to provide insights into a potentially more effective treatment option for patients suffering from this disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple-negative breast cancer, particularly those who have not responded well to existing treatments.
Not a fit: Patients with other subtypes of breast cancer or those who are not diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that significantly improves outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Preliminary results from similar research have shown promise, indicating that LG007 could be a potent drug candidate for treating progressive TNBC.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Xi, Yaguang — University of Georgia
- Study coordinator: Xi, Yaguang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.